Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 663-670

  Straus, David J ^a   Hamlin, Paul A ^a   Matasar, Matthew J ^a   Lia Palomba, Maria ^a   Drullinsky, Pamela R ^b   Zelenetz, Andrew D ^a   Gerecitano, John F ^a   Noy, Ariela ^a   Hamilton, Audrey M ^c   Elstrom, Rebecca ^d   Wegner, Brett ^a   Wortman, Katy ^e   Cella, David ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Memorial Sloan Kettering Rockville Centre   (United States)

^c Memorial Sloan Kettering Basking Ridge   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Combination; Diffuse large B cell lymphoma; Elderly; Relapsed refractory; Vorinostat

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; FILGRASTIM; PEGFILGRASTIM; PREDNISONE; RITUXIMAB; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; MONOCLONAL ANTIBODY; PREDNISOLONE;

AGED; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TOXICITY; BRAIN ISCHEMIA; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELDERLY CARE; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FRAIL ELDERLY; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; LARGE CELL LYMPHOMA; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; THROMBUS; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; AUTOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PALLIATIVE THERAPY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOGRAFTS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MAXIMUM TOLERATED DOSE; PALLIATIVE CARE; PREDNISOLONE; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84922771286     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13195     Document Type: Article

References (34)

1. Aribi, M., Mesli, N., Remla, N., Sari, B.E., Taleb, A., Touhami, H., Bekadja, M.A., Zouaoui-Benhadji, Z., Bouzid, K. & Meguenni, K. (2010) Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria. J Cancer Res Ther, 6, 41-46.
2. Brucker, P.S., Yost, K., Cashy, J., Webster, K. & Cella, D. (2005) General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Evaluation and the Health Professions, 28, 192-211.
3. Cella, D., Webster, K., Cashy, J., Kutikova, L., Burgess, M.F., Lin, B.K., Bowman, L., Liepa, A.M., Gauthier, J.E., Gregory, S.A., Johnson, S.A. & Cheson, B.D. (2005) Development of a measure of health-related quality of life fo non-Hodgkin's lymphoma clinical research: the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym). Blood (ASH Annual Meeting Abstracts), 106, Abstract 750.
4. Chao, N.J., Rosenberg, S.A. & Horning, S.J. (1990) CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood, 76, 1293-1298.
5. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
6. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
7. Copeland, A., Buglio, D. & Younes, A. (2010) Histone deacetylase inhibitors in lymphoma. Current Opinion in Oncology, 22, 431-436.
8. Crump, M., Coiffier, B., Jacobsen, E.D., Sun, L., Ricker, J.L., Xie, H., Frankel, S.R., Randolph, S.S. & Cheson, B.D. (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Annals of Oncology, 19, 964-969.
9. Gisselbrecht, C., Schmitz, N., Mounier, N., Singh Gill, D., Linch, D.C., Trneny, M., Bosly, A., Milpied, N.J., Radford, J., Ketterer, N., Shpilberg, O., Duhrsen, U., Hagberg, H., Ma, D.D., Viardot, A., Lowenthal, R., Briere, J., Salles, G., Moskowitz, C.H. & Glass, B. (2012) Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. Journal of Clinical Oncology, 30, 4462-4469.
10. Griffin, M.M. & Morley, N. (2013) Rituximab in the treatment of non-Hodgkin's lymphoma-a critical evaluation of randomized controlled trials. Expert Opin Biol Ther, 13, 803-811.
11. Hamaker, M.E., Stauder, R. & van Munster, B.C. (2014) On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Annals of Oncology, 25, 675-681.
12. Hamlin, P.A., Zelenetz, A.D., Kewalramani, T., Qin, J., Satagopan, J.M., Verbel, D., Noy, A., Portlock, C.S., Straus, D.J., Yahalom, J., Nimer, S.D. & Moskowitz, C.H. (2003) Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood, 102, 1989-1996.
13. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Muller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O. & Chan, W.C. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 103, 275-282.
14. Hasselblom, S., Stenson, M., Werlenius, O., Sender, M., Lewerin, C., Hansson, U., Nilsson-Ehle, H. & Andersson, P.O. (2012) Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leukaemia & Lymphoma, 53, 394-399.
15. Hosing, C., Saliba, R.M., Okoroji, G.J., Popat, U., Couriel, D., Ali, T., De Padua Silva, L., Kebriaei, P., Alousi, A., De Lima, M., Qazilbash, M., Anderlini, P., Giralt, S., Champlin, R.E. & Khouri, I. (2008) High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Annals of Oncology, 19, 1166-1171.
16. Ivy, S.P., Siu, L.L., Garrett-Mayer, E. & Rubinstein, L. (2010) Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clinical Cancer Research, 16, 1726-1736.
17. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
18. Kim, M.S., Blake, M., Baek, J.H., Kohlhagen, G., Pommier, Y. & Carrier, F. (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Research, 63, 7291-7300.
19. Lanic, H., Kraut-Tauzia, J., Modzelewski, R., Clatot, F., Mareschal, S., Picquenot, J.M., Stamatoullas, A., Lepretre, S., Tilly, H. & Jardin, F. (2013) Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leukaemia & Lymphoma, 55, 817-823.
20. Marchion, D.C., Bicaku, E., Turner, J.G., Daud, A.I., Sullivan, D.M. & Munster, P.N. (2005) Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clinical Cancer Research, 11, 8467-8475.
21. Morschhauser, F., Illidge, T., Huglo, D., Martinelli, G., Paganelli, G., Zinzani, P.L., Rule, S., Liberati, A.M., Milpied, N., Hess, G., Stein, H., Kalmus, J. & Marcus, R. (2007) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood, 110, 54-58.
22. Mounier, N., El Gnaoui, T., Tilly, H., Canioni, D., Sebban, C., Casasnovas, R.O., Delarue, R., Sonet, A., Beaussart, P., Petrella, T., Castaigne, S., Bologna, S., Salles, G., Rahmouni, A., Gaulard, P. & Haioun, C. (2013) Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica, 98, 1726-1731.
23. Nabhan, C., Smith, S.M., Helenowski, I., Ramsdale, E., Parsons, B., Karmali, R., Feliciano, J., Hanson, B., Smith, S., McKoy, J., Larsen, A., Hantel, A., Gregory, S. & Evens, A.M. (2012) Analysis of very elderly (>/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. British Journal of Haematology, 156, 196-204.
24. Niitsu, N., Kohuri, M., Higashihara, M. & Bessho, M. (2006) Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Science, 97, 933-937.
25. O'Connor, O.A., Heaney, M.L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., Zelenetz, A.D., Frankel, S., Richon, V., Marks, P. & Kelly, W.K. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of Clinical Oncology, 24, 166-173.
26. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M. & Duvic, M. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109-3115.
27. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H., Bron, D., Sonneveld, P., Gisselbrecht, C., Cahn, J.Y., Harousseau, J.L., Coiffier, B., Biron, P., Mandelli, F. & Chauvin, F. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New England Journal of Medicine, 333, 1540-1545.
28. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Reaearch on Cancer (IARC), Lyon.
29. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987-994.
30. Thieblemont, C., Grossoeuvre, A., Houot, R., Broussais-Guillaumont, F., Salles, G., Traulle, C., Espinouse, D. & Coiffier, B. (2008) Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Annals of Oncology, 19, 774-779.
31. Trebouet, A., Marchand, T., Lemal, R., Gyan, E., Broussais-Guillaumot, F., Guillermin, Y., Monjanel, H., Salles, G., Le Gouill, S., Godmer, P., Fruchart, C., Damaj, G., Feugier, P., Thieblemont, C., Maynadie, M., Monnereau, A., Troussard, X., Rossille, D., Lamy, T. & Houot, R. (2013) Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA. Annals of Oncology, 24, 2612-2618.
32. Vacirca, J.L., Acs, P.I., Tabbara, I.A., Rosen, P.J., Lee, P. & Lynam, E. (2014) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Annals of Hematology, 93, 403-409.
33. Xu, W.S., Parmigiani, R.B. & Marks, P.A. (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 26, 5541-5552.
34. Zinzani, P.L., Pellegrini, C., Gandolfi, L., Stefoni, V., Quirini, F., Derenzini, E., Broccoli, A., Argnani, L., Pileri, S. & Baccarani, M. (2011) Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk, 11, 462-466.